Clinical trials
Metastatic Breast Cancer clinical trials
Below are recruiting metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 1,312 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05848141Recruiting
Rowing program after breast cancer treatment
This study looks at whether supervised rowing exercise after breast cancer treatment is safe and helpful for recovery and health. You may be able to join if you finished treatment within the last 6–24 months and have no major exercise-limiting heart or health problems.
Gainesville, FloridaAges 40–80 - NCT05831878Recruiting
Drug RC48 for HER2-low or HER2-ultralow breast cancer
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
ShanghaiAges 18 years+ - NCT05798338Recruiting
Study blood samples and tiny cell particles in breast cancer
This study looks at tiny particles released by cells (called extracellular vesicles) in people with breast cancer. It may help researchers better understand breast cancer and how it behaves, which could improve future testing or treatments.
Pavia, LombardyAges 18–90 - NCT05528133RecruitingPhase 2
Personalized radiation based on tumor genetics in triple-negative breast cancer
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Clearwater, FloridaAges 18 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05398861RecruitingPhase 2
Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Zhengzhou, HenanAges 18–70 - NCT05074290RecruitingPhase 1/Phase 2
Testing safety and drug levels of a breast cancer drug plus taxane
This early-phase study tests how epidiferphane works in the body and whether it is safe when combined with standard chemotherapy “taxanes” (paclitaxel or docetaxel) for breast cancer. If you qualify, you may be starting a new taxane treatment plan at the study site, and you would be followed closely for side effects and drug levels.
Gainesville, FloridaAges 18–99 - NCT05035836RecruitingPhase 2
Test drug after early HER2-positive breast cancer surgery
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Houston, TexasAges 18 years+ - NCT04680715RecruitingPhase 2
Tested radiation before and after breast surgery in older women
This Phase 2 trial looks at a specific radiation timing and technique around the time of breast-conserving surgery. It may help reduce the chance the cancer comes back in selected older patients with certain early-stage, hormone-positive, HER2-negative breast cancers.
Clermont-FerrandAges 65 years+ - NCT01000883Recruiting
Biopsy study linking breast cancer tissue markers to treatment response
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
Chapel Hill, North CarolinaAges 18 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06631092RecruitingPhase 1/Phase 2
Personalized cancer vaccine with standard therapy for triple-negative breast cancer
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
ErlangenAges 18 years+ - NCT06583070Recruiting
SABR plus targeted therapy and immunotherapy for advanced kidney cancer
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT06435351RecruitingEarly Phase 1
Personalized vaccine for high-risk triple-negative breast cancer
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT04923542RecruitingPhase 1/Phase 2
Targeted drug plus focused brain radiation for breast cancer
This study tests whether abemaciclib (a targeted pill) given with focused radiation to brain tumors can control hormone receptor–positive, HER2-negative breast cancer in the brain. It’s designed to see if the combination helps shrink or slow the growth of brain metastases while keeping side effects manageable.
Tampa, FloridaAges 18 years+ - NCT03769415Recruiting
Using tumor gene data to improve treatment in metastatic breast cancer
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
Chapel Hill, North CarolinaAges 18–99 - NCT06449937Recruiting
Local liver treatment for colorectal cancer that has spread
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
Chuzhou, AnhuiAges 18–80 - NCT07797218RecruitingPhase 3
Comparing two drug combinations before breast cancer surgery
This study is comparing two different drug combinations given before breast cancer surgery. The goal is to see which one shrinks tumors more effectively. This type of treatment is called 'neoadjuvant' therapy.
ShanghaiAges 18–70 - NCT05241405Recruiting
American ginseng to reduce fatigue after cancer treatment
This study tests whether taking American ginseng for 8 weeks can lessen long-lasting tiredness (fatigue) in people who recently finished certain breast or gynecologic cancer treatments. It may help reduce fatigue when other causes have been ruled out.
AmiensAges 18 years+ - NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT07679360RecruitingPhase 3
New drug combo for residual triple-negative breast cancer after surgery
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer?
- Yes. Clin2 currently lists 1,312 recruiting metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced or Metastatic Breast Cancer
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Advanced/Metastatic Breast Cancer
- Non-metastatic Breast Cancer
- Advanced or Metastatic Breast Cancer
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.